Group
Companies
History
Business model
Mission and vision
Corporate values
Commitment to sport
Research
Pharmaceutical Research
Sucrosomial Technology
Cetylated Fatty Acids
Quality and certifications
Brands
PharmaNutra
Alesco
Akern
Investor
INVESTOR RELATIONS
Stock performance
Share capital and Shareholders
Shares study and research
Broker
Financial statements
Presentations
Corporate events
Company presentation
Notice of meetings
SDIR
AIM admission document
MTA prospectus
PRESS
Press releases
Press review
Governance
Code of Ethics
231 Model
Board of Directors and Committees
Company documents
Internal dealing
Shareholders’ meeting
Statutory auditors and Audit firm
Sharholders Agreements
Sustainability
News
Science
Corporate
Events
Social commitment
Careers
Work with us
Job offers
Job application
Group
Companies
History
Business model
Mission and vision
Corporate values
Commitment to sport
Research
Pharmaceutical Research
Sucrosomial Technology
Cetylated Fatty Acids
Quality and certifications
Brands
PharmaNutra
Alesco
Akern
Investor
INVESTOR RELATIONS
Stock performance
Share capital and Shareholders
Shares study and research
Broker
Financial statements
Presentations
Corporate events
Company presentation
Notice of meetings
SDIR
AIM admission document
MTA prospectus
PRESS
Press releases
Press review
Governance
Code of Ethics
231 Model
Board of Directors and Committees
Company documents
Internal dealing
Shareholders’ meeting
Statutory auditors and Audit firm
Sharholders Agreements
Sustainability
News
Science
Corporate
Events
Social commitment
Careers
Work with us
Job offers
Job application
it
en
Category:
18 December 2024
2025 CORPORATE EVENTS CALENDAR PUBLICATION
25 November 2024
DISTRIBUTION AGREEMENT FOR SIDERAL® PRODUCTS SIGNED IN CANADA
18 November 2024
FIRST SIGNIFICANT SALES RESULTS IN CHINA
11 November 2024
PHARMANUTRA S.P.A.: THE BOD APPROVES THE INTERIM MANAGEMENT REPORT AS AT SEPTEMBER 30, 2024
04 November 2024
PHARMANUTRA S.P.A. APPLIES ITS PROPRIETARY SUCROSOMIAL® TECHNOLOGY TO VITAMINS AND LAUNCHES NEW SIDEVIT® LINE
29 October 2024
AGREEMENT WITH AN INTERNATIONAL ADVISOR IN ORDER TO DEFINE A DEVELOPMENT PLAN FOR PHARMANUTRA USA
02 October 2024
ALLEGATO 3F – SETTEMBRE 2024
09 September 2024
BOD APPROVED THE FIRST HALF FINANCIAL REPORT AS AT 30 JUNE 2024
03 September 2024
ALLEGATO 3F – AGOSTO 2024
03 September 2024
LAUNCH OF TWO SIDERAL® PRODUCTS IN GERMANY
01 August 2024
ALLEGATO 3F – LUGLIO 2024
24 July 2024
Significant Sales and Market Positioning Results in the Italian Nutraceutical Market
08 July 2024
Allegato 3F Giugno 2024
05 July 2024
Effectiveness of the merger by incorporation
22 June 2024
Internal dealing communication
18 June 2024
THE DISTRIBUTION OF IRON-BASED DIETARY SUPPLEMENTS KICKS OFF IN MEXICO
13 June 2024
A NEW STUDY HIGHLIGHTS THE EFFICACY, SUPERIORITY AND IMPROVED TOLERABILITY OF SIDERAL® COMPARED TO CONVENTIONAL IRON SUPPLEMENT TREATMENTS
12 June 2024
INITIATION OF SHARE BUY-BACK PROGRAM
29 May 2024
ASSUNZIONE QUALIFICA DI PMI
13 May 2024
PHARMANUTRA S.P.A. THE BOD APPROVES THE INTERIM MANAGEMENT REPORT AS AT 31 MARCH2024 AND THE 2023 SUSTAINABILITY REPORT
15 April 2024
THE MERGER BY INCORPORATION INTO PHARMANUTRA S.P.A. OF JUNIA PHARMA S.R.L. AND ALESCO S.R.L. HAS BEEN APPROVED
1
2
…
11
>